Federal Supply Schedule 36F79724D0159

Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer, holds several significant Indefinite Delivery Vehicles (IDVs) with the U.S. federal government, primarily focused on supplying specialized drug therapies to federal healthcare institutions. The company's primary IDVs include a $219,108,390 Federal Supply Schedule (FSS-61-IB) contract with the Department of Veterans Affairs (VA), as well as two Blanket Purchase Agreements (BPAs) valued at $118.5 million and $83.5 million. These contract vehicles enable the VA, Federal Bureau of Prisons, and other civilian federal agencies to efficiently procure a range of medications, predominantly for the treatment of rare diseases and pulmonary arterial hypertension, such as Uptravi, Opsumit, Veletri, Adempas, and Tyvaso. The delivery orders issued under these IDVs, valued from small procurements of $12,000 to larger bulk orders exceeding $700,000, are structured as firm fixed-price contracts without any small business set-aside designations, reflecting Actelion's status as a large pharmaceutical manufacturer serving specialized federal healthcare needs.

The federal contract awards to Actelion Pharmaceuticals US, Inc. provide critical pharmaceutical products to federal agencies, including the VA, Federal Correctional Complexes, and Federal Medical Centers, to support the medical needs of veterans, inmates, and other eligible beneficiaries. The contract vehicles facilitate streamlined procurement processes and pre-negotiated pricing for these specialized drug therapies, which are essential for treating complex conditions like pulmonary arterial hypertension. The geographic scope of the contract performance is primarily centered in the southeast region of the United States, with deliveries to locations in Florida, Tennessee, and Texas.